Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
NCT ID: NCT03902080
Last Updated: 2024-08-07
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1105 participants
INTERVENTIONAL
2019-03-26
2023-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
NCT03492281
An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).
NCT03583372
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)
NCT01314872
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00662909
Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder
NCT00479505
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vibegron 75 mg
Participants will receive vibegron 75 milligrams (mg) orally once daily for 24 weeks.
Vibegron
oral administration
Placebo
Participants will receive matching placebo orally once daily for 24 weeks.
Placebo
oral administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vibegron
oral administration
Placebo
oral administration
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant has an International Prostate Symptom Score total score of ≥ 8
* Participant has a prostate-specific antigen level \< 4 nanograms per milliliter (ng/mL), or if ≥ 4 ng/mL but ≤ 10 ng/mL, prostate cancer has been ruled out to the satisfaction of the investigator
* Participant must have both additional qualifications based on the 3-day Bladder Diary period: a) having an average of ≥ 8 but ≤ 20 micturition episodes per day over the 3-day diary period, and (b) having an average of ≥ 3 urgency episodes per day over the 3-day diary period
* Participant must have a post void residual volume value of \< 100 mL
* Having at least 2 average nocturia episodes per night based on 3-day Bladder Diary at baseline. Nocturia is defined as waking to pass urine during the main sleep period.
Exclusion Criteria
* Has lower urinary tract pathology that could, in the opinion of the investigator, be responsible for urgency, frequency, or incontinence
* Has a history of prostate surgery, including minimally invasive transurethral or transrectal procedures, procedural treatments for BPH within 6 months of Screening or has a planned prostate surgery
* Has a history of urinary retention requiring an intervention (e.g., catheterization) for any reason
* Has maximum urinary flow (Qmax) \< 5.0 mL/second with a minimum voided volume of 125 mL
* Has a history of or current nocturnal polyuria
* Has an active or recurrent (\> 3 episodes per year) urinary tract infection by clinical symptoms or laboratory criteria (≥ 5 white blood cells/high power field \[hpf\] with presence of red blood cell \[RBC\] and/or a positive urine culture, defined as ≥ 10\^5 colony forming units (CFU)/mL (i.e., 100 × 10\^3 CFU/mL in a single specimen)
* Has uncontrolled hyperglycemia (defined as fasting blood glucose \> 150 milligrams per deciliter (mg/dL) or 8.33 millimoles per liter (mmol/L) or non-fasting blood glucose \> 200 mg/dL or 11.1 mmol/L) or, if in the opinion of the investigator, is uncontrolled
* Has uncontrolled hypertension (systolic blood pressure of ≥ 180 millimeters of mercury (mmHg) and/or diastolic blood pressure of ≥ 100 mmHg) or has a resting heart rate (by pulse) \> 100 beats per minute (min)
* Has a history of cerebral vascular accident, transient ischemic attack, unstable angina, myocardial infarction, coronary artery interventions (e.g., coronary artery bypass grafting or percutaneous coronary interventions \[e.g., angioplasty, stent insertion\]), or neurovascular interventions (e.g., carotid artery stenting) within 6 months prior to the Screening Visit
* Has alanine aminotransferase or aspartate aminotransferase \> 2.0 times the upper limit of normal (ULN), or bilirubin (total bilirubin) \> 1.5 × ULN (or \> 2.0 × ULN if secondary to Gilbert syndrome or pattern consistent with Gilbert syndrome)
* Has an estimated glomerular filtration rate \< 30 mL/min/1.73 meters squared (m\^2)
* Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstances that might, in the opinion of the investigator, confound the results of the study, interfere with the participant's ability to comply with the study procedure, or make participation in the study not in the participant's best interest
45 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Urovant Sciences GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Urovant Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Urology Centers of Alabama
Homewood, Alabama, United States
Private Practice
Huntsville, Alabama, United States
Coastal Clinical Research, Inc.
Mobile, Alabama, United States
Gen1 Research- Arizona Urology Specialists
Glendale, Arizona, United States
Urological Associates Of Southern Arizona
Tucson, Arizona, United States
California Research Medical Group, Inc.
Fullerton, California, United States
San Diego Clinical Trials
La Mesa, California, United States
Clinical Trials Research
Lincoln, California, United States
West Coast Urology
Los Alamitos, California, United States
American Institute of Research
Los Angeles, California, United States
Norris Comprehensive Cancer Center
Los Angeles, California, United States
Tri Valley Urology Medical Group
Murrieta, California, United States
Northern California Research Corp
Sacramento, California, United States
Medical Center for Clinical Research
San Diego, California, United States
Urology Specialists of Southern California (USSC)
Sherman Oaks, California, United States
Skyline Urology
Torrance, California, United States
Urology Associates - Urology
Denver, Colorado, United States
Imagine Research of Palm Beach County - Urology
Boynton Beach, Florida, United States
Tampa Bay Medical Research
Clearwater, Florida, United States
Urological Research Network Corp
Hialeah, Florida, United States
LCC Medical Research Institute
Miami, Florida, United States
Quantum Clinical Trials
Miami, Florida, United States
Private Practice
Orlando, Florida, United States
Urology Center Of Florida
Pompano Beach, Florida, United States
Pinellas Urology, Inc.
St. Petersburg, Florida, United States
Precision Clinical Research
Sunrise, Florida, United States
Florida Urology Partners, LLP
Tampa, Florida, United States
Clinical Research of Central Florida
Winter Haven, Florida, United States
Meridian Clinical Research - Urology
Savannah, Georgia, United States
Idaho Urologic Institute
Meridian, Idaho, United States
NorthShore University Health System
Glenview, Illinois, United States
First Urology
Jeffersonville, Indiana, United States
The Iowa Clinic
West Des Moines, Iowa, United States
GU Research Network/Wichita Urology Group
Wichita, Kansas, United States
DelRicht Research
New Orleans, Louisiana, United States
Regional Urology, LLC
Shreveport, Louisiana, United States
Chesapeake Urology Research Associates
Baltimore, Maryland, United States
Boston Clinical Trials Inc - Urology
Boston, Massachusetts, United States
Mens Health Boston - Urology
Chestnut Hill, Massachusetts, United States
Bay State Clinical Trials, Inc.
Watertown, Massachusetts, United States
Beaumont Hospital Royal Oak - Urology Research
Royal Oak, Michigan, United States
CentraCare Clinic - Adult & Pediatric Urology
Sartell, Minnesota, United States
Poplar Bluff Urology
Poplar Bluff, Missouri, United States
Adult & Pediatric Urology P.C. - Urology
Omaha, Nebraska, United States
Excel Clinical Research - Internal Medicine
Las Vegas, Nevada, United States
Private Practice
Las Vegas, Nevada, United States
Premier Urology Group, LLC
Edison, New Jersey, United States
New Jersey Urology NJU
Englewood, New Jersey, United States
New Jersey Urology, LLC
Mount Laurel, New Jersey, United States
New Jersey Urology, LLC
Voorhees Township, New Jersey, United States
Albany Medical College
Albany, New York, United States
Western New York Urology Associates
Buffalo, New York, United States
AccuMed research Asociates
Garden City, New York, United States
Urological Surgeons of Long Island
Garden City, New York, United States
Manhattan Research Associates
New York, New York, United States
Columbia University Medical Center - Clinical Research
New York, New York, United States
Weill Cornell Medicine
New York, New York, United States
Advanced Urology Centers of NY, A Division of Integrated Medical Professionals (IMP)
Plainview, New York, United States
Private Practice
Poughkeepsie, New York, United States
Duke Medical Center - Urology
Durham, North Carolina, United States
Carolina Institute for Clinical Research
Fayetteville, North Carolina, United States
Alliance Urology Specialists - Greensboro
Greensboro, North Carolina, United States
Triad Clinical Trials
Greensboro, North Carolina, United States
Peters Medical Research
High Point, North Carolina, United States
Associated Urologists of North Carolina - Urology
Raleigh, North Carolina, United States
Clinical Research Solutions
Middleburg Heights, Ohio, United States
Lowcountry Urology
North Charleston, South Carolina, United States
Urology Clinics of North Texas
Dallas, Texas, United States
Advances In Health, Inc.
Houston, Texas, United States
Urology San Antonio
San Antonio, Texas, United States
Discovery Clinical Trials
San Antonio, Texas, United States
Baylor Scott & White Medical Center
Temple, Texas, United States
Wasatch Clinical Research LLC
Salt Lake City, Utah, United States
Urology of Virginia (UVA)
Virginia Beach, Virginia, United States
Seattle Urology Research Center
Burien, Washington, United States
Uz Antwerpen
Edegem, Antwerpen, Belgium
Algemeen Stedelijk Ziekenhuis
Aalst, Oost-Vlaanderen, Belgium
Onze-Lieve-Vrouwziekenhuis VZW - Campus Aalst
Aalst, Oost-Vlaanderen, Belgium
AZ Maria Middelares - Campus Maria Middelares
Ghent, Oost-Vlaanderen, Belgium
UZ Leuven - Campus Gasthuisberg
Leuven, Vlaams Brabant, Belgium
AZ Delta - Campus Wilgenstraat
Roeselare, West-Vlaanderen, Belgium
CHU de Liège - Domaine Universitaire du Sart Tilman - Urologie
Liège, , Belgium
Private Practice
Brampton, Ontario, Canada
Bluewater Clinical Research Group Inc
Sarnia, Ontario, Canada
Sunnybrook Health Sciences Center
Toronto, Ontario, Canada
Toronto Western Hospital
Toronto, Ontario, Canada
Diex Research Quebec Inc.
Québec, Quebec, Canada
Centre Hospitalier Universitaire De Sherbrooke (CHUS)
Sherbrooke, Quebec, Canada
Diex Research Sherbrooke Inc.
Sherbrooke, Quebec, Canada
Diex Research Victoriaville Inc.
Victoriaville, Quebec, Canada
University of Szeged
Szeged, Csongrád megye, Hungary
DRC Kft.
Sopron, Győr-Moson-Sopron, Hungary
Semmelweis Egyetem
Budapest, , Hungary
Jahn Ferenc Dél-Pesti Kórház és Rendelointézet
Budapest, , Hungary
Szarka Ödön Egyesitett Egeszsegügyi es Szocialis Intezmeny
Csongrád, , Hungary
Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókór
Nyíregyháza, , Hungary
Uro-Clin Kft.
Pècs, , Hungary
Szent Borbala Korhaz
Tatabánya, , Hungary
Kaunas Hospital of Lithuanian Universoity of Health Sciences
Kaunas, Kaunas County, Lithuania
JSC Saules seimos medicinos centras
Kaunas, Kaunas County, Lithuania
Uab "Vakk"
Kaunas, Kaunas County, Lithuania
Hospital of University of Health Sciences Kauno Klinikos
Kaunas, Kaunas County, Lithuania
Respublikine Klaipedos ligonine - Urology
Klaipėda, Klaipėda County, Lithuania
Klaipedos Universitetine Ligonine (Klaipeda Hospital)
Klaipėda, Klaipėda County, Lithuania
National Cancer Institute
Vilnius, Vilnius County, Lithuania
Republican Vilnius University Hospital
Vilnius, Vilnius County, Lithuania
Vilnius University Hospital Santariskiu Klinikos
Vilnius, Vilnius County, Lithuania
Vilnius City Clinical Hospital
Vilnius, Vilnius County, Lithuania
EuroMediCare Szpital Specjalistyczny z Przychodnia
Wroclaw, Dolnoslaskie Województwo, Poland
Clinical Research Center Sp. z o.o., Medic-R Sp. K.
Poznan, Greater Poland Voivodeship, Poland
Nasz Lekarz Osrodek Badan Klinicznych
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Wojewodzki Szpital Specjalist
Wroclaw, Lower Silesian Voivodeship, Poland
NZOZ Specjalista
Kutno, Lódzkie, Poland
ETG Lodz
Lodz, Lódzkie, Poland
Centrum Medyczne PROMED
Krakow, Malopolskie Województwo, Poland
Szpital Specjalistyczny Slupsk
Słupsk, Pomeranian Voivodeship, Poland
Centrum Urologiczne sp. z o.o.
Mysłowice, Silesian Voivodeship, Poland
Centrum Medyczne Linden
Krakow, , Poland
Medicome Sp. z o.o.
Oświęcim, , Poland
Nzoz Heureka
Piaseczno, , Poland
Lexmedica Hanna Durbajlo-Gradziel
Wroclaw, , Poland
Hospital Garcia de Orta
Almada, , Portugal
Centro Clínico Académico Braga, Hospital de Braga
Braga, , Portugal
Hospital Senhora de Oliveiro Guimaraes EPE
Guimarães, , Portugal
H. Egas Moniz. Centro Hospitalar Lisboa Ocidental
Lisbon, , Portugal
Hospital de Santa Maria
Lisbon, , Portugal
H. Santo António. Centro Hospitalar do Porto
Porto, , Portugal
Hospital Santiago Apostol
Miranda de Ebro, Burgos, Spain
Hospital Universitario Fundación Alcorcón
Alcorcón, Madrid, Spain
Hospital Universitario HM Monteprincipe
Boadilla del Monte, Madrid, Spain
Hospital General Universitario Gregorio Marañón
Majadahonda, Madrid, Spain
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Madrid, Spain
Hospital Universitario Infanta Sofía
San Sebastián de los Reyes, Madrid, Spain
Hospital del Mar
Barcelona, , Spain
Hospital Universitario Reina Sofia
Córdoba, , Spain
Clínica Universitaria de Navarra
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
H.U. Virgen de la Victoria
Málaga, , Spain
Hospital Universitario de Salamanca
Salamanca, , Spain
Hospital Universitari i Politecnic La Fe
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-003135-30
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
URO-901-3005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.